in vivo 11
DESCRIPTION
In Vivo issue 11 July 2010TRANSCRIPT
July 2010 | Issue 11July 2010 | Issue 11
05 06 07 08Family Day at IRB Barcelona
Faces to Names: Interview with Angel R Nebreda
Mission: discover your workplace
A cross-Atlantic connection
NEWSLETTER OF THE INSTITUTE FOR RESEARCH IN BIOMEDICINE
in vivoIn Focus
A close look at the research carried out at the IRB Barcelona Colorectal Cancer Laboratory
Staking out the future of the ERC
IRB Barcelona hosted key players from the ERC to discuss the future of the or-ganization in May
Page 02
Mingling with laureates
Five young IRB Barcelona researchers were selected to represent Spain at the Lindau Nobel Laureate meeting
Page 03
Investing in excellence
Ten PhD students received their “la Caixa”/IRB Barcelona International PhD fellowship awards in July
Page 03
Page 02
A glimpse beyond the bench
An opinion article about the alternative career paths available for researchers who want to pursue new challenges
Page 04
On the Spot
Nobel laureate Robert Huber, who vis-ited IRB Barcelona in May to present his latest research work, talks about his expe-rience after winning the Nobel Prize
Page 04
in vivoJuly 2010 | Issue 11
Beyond a doubt, the introduction of the European Research Council, es-
tablished under the EU’s FP7, has inject-ed a breath of life into frontier research in Europe. With 7.5 billion euros to be awarded over a 7-year span, it has provid-ed a direly needed resource for scientists engaged in research of excellence in Eu-rope. The fact that more than 15,400 ap-plications for its Starting and Advanced Grant schemes have been received so far, and that the 1000th award has recently been granted, are clear indications that ERC has filled an important hole in European funding schemes.
Everything, however, is not a bed of roses. In July 2009 a high level panel pub-lished a review of the ERC’s structures and mechanisms which, while recogniz-ing the outstanding achievements, pro-vided strong recommendations to address “fundamental problems related to rules
and practices regarding the governance, administration and operations of the ERC that are not adapted to the nature of modern ‘frontier’ science management.”
The scientific community and policy makers met to review the achievements of the ERC and to consider how it can develop in the future into the stable and performing institution that is desired. ‘ERC: From Programme to Institution’ was held at the ‘Institut d’Estudis Catalans’ (IEC) on May 28, organized by the Ini-tiative for Science in Europe in collabo-ration with IRB Barcelona.
The third leading cause of cancer-related deaths in the Western world has a strong opponent. Researchers at the
IRB Barcelona Colorectal Cancer Laboratory are hard at work to find new clues to fight cancerous growths in the colon. The lab’s breakthrough findings in colon cancer won group leader Eduard
Normal intestinal stem cells, which are crucial to help regenerate the walls of the in-testine throughout a person’s lifetime, can be-come their worst enemy and lead to colon can-cer when they accumulate specific mutations.
This breakthrough finding, published by Batlle a few years ago, led the laboratory to explore the connection between healthy and cancerous intestinal stem cells with the hope to unravel the keys that allow malignant cells
Batlle the ‘Banc de Sabadell’ Prize for Biomedical Research in June. The laboratory will soon be releasing new work on the mechanisms that allow cancer stem cells to regenerate and make tumors grow. The team led by Batlle is convinced that the answer lies in normal intestinal stem cells, also present in tumors.
A strong opponent in the battle against colon cancer
IN FOCUS
Staking out the future of the ERC Reaching the frontier
The ERC is a powerful mechanism to drive research of excellence and
its establishment has brought with it huge potential and expectations. The first call in 2007 was met with a stag-gering 9,167 applications, only 250 of which were awarded funding. With such steep competition, what are the fac-tors that make the difference? Which characteristics must a researcher have to tap into this resource? What role do universities, research institutes, regions and governments play and how can they contribute to chances for success?
Key players from the ERC, together with local and national science policy makers, as well as researchers who have received ERC grants met on May 27 at the Barcelona BioMed Forum ‘Reach-ing the Frontier: How to Achieve Suc-cess with the ERC’ to examine the factors that have enabled them to take advantage of this important resource.
ERC President Helga Nowotny discusses the current state of the ERC and future perspectives in Barcelona on May 28. Photo: N. Barbería
to escape and regenerate the tumor. The team has recently found new answers that could one day open the door to new therapies to fight colon cancer. “Our new hypothesis is that tumors in the intestine grow thanks to cancerous stem cells that are adopting mech-anisms of regeneration similar to those used by healthy stem cells,” says Batlle. “The ul-timate goal is to unravel these similarities to find a new drug that blocks the capacity of
malignant stem cells to replicate.” If the lab succeeds in their quest, patients could one day benefit from this drug as a complement to chemotherapy to reduce the chances of re-lapse after surgery.
Dr Jekyll and Mr Hyde
Researchers at the Colorectal Cancer Labo-ratory have also been working against the clock to find the dark side of TGFb, a mol-
in vivoJuly 2010 | Issue 11
03
Tanya Yates
ecule that is well known for its beneficial capacity to suppress tumor growth in the colon.
Apparently, this mol-ecule could also be acting as an ally for cancerous cells to help the tumor grow. “TGFb is like Dr Jekyll and Mr Hyde,” ex-plains research associate Elena Sancho. She says the team has found that all the lab experiments run in mice with real cancer cells from patients indicate that TGFb in cancerous growths can help the tumor grow and metastasize.
The long-term benefits of this find-ing, which will soon be released, are promising. “The development of new therapeutic agents against TGFb or its downstream effectors may have dramatic benefits for colorectal cancer treatment. We are seeking future collaborations with pharmaceutical companies that are begin-ning to focus on this signalling molecule.”
Can you imagine sitting at the same table as the scientists who first identified the
AIDS virus or having a chat with the scien-tists who discovered the green fluorescent protein? Thanks to the 60th Lindau Nobel Laureate meeting, which was held from June 27 to July 2, five young researchers at IRB Barcelona now know exactly how this feels.
PhD students Francisco Barriga, Diana Martínez and Roland Pache, and postdoc-toral fellows Zhanna Shcheprova and Amelie Stein were selected among 40,000 applicants from around the world to join this year’s
Young scientists mingle with Nobel laureates
Laureate meeting, attended by 670 young researchers from 70 countries.
Under the motto ‘Educate. Inspire. Connect.’ the annual meeting between No-bel Laureates and new generations of sci-entists has been held in the German city of Lindau since 1950. While the meeting usu-ally focuses on one of the three scientific dis-ciplines of the Nobel Prizes - Physiology or Medicine, Chemistry or Physics -, this year’s event was interdisciplinary with Laureates and young researchers from the three fields.
The five IRB Barcelona researchers found the presentations and speakers to be highly enriching. “Discussing the relevance of systems biology personally with Tim Hunt was a great opportunity,” says Roland Pache. He had the chance to conduct a video interview with the Nobel Laureate for a new Nature film series about young researchers talking about science with Nobel laureates. Diana Martínez also made a video diary that
Nahia Barbería
Investing in excellence
Ten young scientists from IRB Barcelona’s ‘class of 2009’ received their “la Caixa”/
IRB Barcelona International PhD fellowship awards on July 6 in a formal act held in the CaixaForum Madrid involving the Minister of Science, Cristina Garmendia, Juan María Nin, Director General of “la Caixa”, and Jaime La-naspa, Director of the “la Caixa” Foundation.
IRB Barcelona is one of four biomedical research centers in Spain selected by “la Caixa” to participate in this prestigious programme. Each year they fund a total of 40 young sci-entists (10 at IRB Barcelona), who come from across the world to carry out high-level train-ing in the life sciences over a four-year period. Students are selected on the basis of their sci-entific merit, creativity, and interest in research themes developed at the participating institu-tions. This year’s group at IRB Barcelona were chosen from among 272 applicants, and took up their positions in the autumn of 2009, join-ing an increasingly dynamic PhD community, which currently stands at more than 150.
“Initiatives like the “la Caixa” one reflect an enormous commitment to supporting and fostering scientific excellence in Spain,” com-ments fellowship winner Eva De Mol from Belgium. “The generous grants allow us to fo-cus completely on our research work so that we can make the most of the training opportu-nities that IRB Barcelona has to offer.”
was published on the official social media blog of the Lindau meetings, an online platform for science bloggers to write about their personal experiences and impressions of the event. More info at www.lindau.nature.com.
The research on colon cancer carried out by Elena Sancho (left) and Eduard Batlle (right) involves active collaborations with all the major hospitals in Barcelona.
Photo: M
B H
ansen
Colonoscopy, a life saver test
Colon cancer is relatively easy to cure when it’s detected in its early stages. The problem is that many people fail to have routine colonoscopies and when tumors are detected it’s often too late. “If every-one had periodic colonoscopies colon cancer rates would diminish dramatically worldwide,” says Batlle, who recom-mends people over 50 have this test every three to four years as a preventive mea-sure.
Photo: R
. Pache
Countess Bettina Bernadotte, president of the Council for the Lindau Nobel Laureate meetings, during the opening of the event.
Photo: M
. García
04
Huber has been a member of the IRB Barcelona External Advisory Board since its creation.
ON THE SPOT Barcelona BioMed Seminars
“One of the advantages of the Nobel Prize was
that it became easier to get research funding”
S cientists at IRB Barcelona had a top guest this spring. Biochem-
ist and Nobel laureate Robert Huber (Munich, 1937) came from the Max Planck Institute on May 14 to give a lecture on the potential of intracellu-lar protein degradation as part of the ‘Barcelona BioMed Seminars’ series.
Huber’s outstanding contribu-tion to science won him the Nobel Prize in Chemistry in 1988, thanks to a discovery that changed forever the way scientists look at life. “We were the first to unravel the 3D struc-ture of a protein that plays a crucial role in photosynthesis, the most important chemical process on earth.”
- How did your life change after you won the Nobel Prize?“I wouldn’t say it affected my life too much
in the long run. Perhaps one of the best ad-vantages was that it became easier to get re-search funding and very bright PhD students. The first year or two after winning the prize it was pretty stressful though. People placed very high expectations on me, they treated me like I was a scientific hero. I wasn’t!”
- Did the Nobel laureate distinction come as a complete surprise?“I realized we were going to win the Nobel
Prize in the spring of 1988, when the chairman of the Chemistry Committee asked me out of the blue for passport photographs of myself and my colleagues Johann Deisenhofer and Hartmut Michel. That was the only way to get photos in the pre-Internet era! Lucky for us, we were given the prize only three years after the publication of our discovery—the time lapse is usually much longer, sometimes it can even take a lifetime to get it.”
- How did you start out in biochemistry?“It was back in the early sixties, a time when crystallography was still in its infancy. While doing my doctoral thesis I managed to unrav-el the structure of an insect hormone called ecdysone, which turned out to solve the ques-tion of hormonal regulation in insects. Back then insects were still regarded as hormone-less! I worked on this project with Adolf Bu-tenandt, who had won the Nobel Prize for his discovery on human sex hormones.”
- What keeps you going?“Research work can be very frustrating at times, but passion keeps you hooked. Sci-entists are like sailors exploring unknown seas. You’re always hoping to discover new islands.”
An alternative glimpse beyond laboratory work
Finding myself among the speakers in the
second edition of the ‘Career Progres-
sion in Science’ event to present alternatives
to benchwork was a pretty surprising experi-
ence. Until recently, I had never considered
career options outside the laboratory.
In the field of biomedical research, those
of us with a vocation for research are taught
from our final years at university that we have
to join a research lab, train, get a PhD, publish
as many good papers as possible, spend sev-
eral years or seemingly infinite postdoctoral
The ‘Career Progression in Science’ event, held on June 3, was organized by IRB Barcelona and the Barcelona Science Park. Jorge Domínguez (right) left his lab duties in 2009 to become head of Innovation and Strategic Projects at IRB Barcelona.
ing communication skills or knowledge of
legal, financial and marketing aspects.
Career reorientation is definitely a chal-
lenge, but is it worth it? It can definitely be,
not only because of the many employment
opportunities but also the ongoing chances
for self-development. Among the alterna-
tive career options, we can enter, for instance,
the complex - and often poorly understood
- world of technology transfer, science com-
munication, the integral management of in-
creasingly complex European projects, cor-
porate sales structures, and the management
of biotech companies.
‘Stay hungry, stay lean’, a recommenda-
tion I recently read regarding scientific excel-
lence, is a highly appropriate motto for the
alternative career opportunities that were
brought to the table on June 3.
Jorge Domínguez
stages abroad, and, final-
ly, head a research group.
There is, however, a
whole world waiting out
there that is equally or
even more exciting than
work in a lab, and you
don’t have to abandon
research to enter it. Sci-
entists can make a great contribution to the
‘outside world’. We can offer our knowledge
of research and of the singularities so charac-
teristic of our colleagues, and also the critical
and evaluation capacity that we have devel-
oped in response to the innumerable occa-
sions on which we have been evaluated.
Stepping out of the lab to find alternative
career paths can be a rewarding experience
if one knows how to take advantage of the
training opportunities available to strengthen
the weak points a scientist may lack, includ-
Anna Alsina
05
What did you do at work today, dear? For many, this may be a common dinner-table question with a relatively straight-
forward answer. Not necessarily so, however, for IRB Barcelona researchers who often find themselves having to explain the West-ern Blot they did or the metagenomic data they analysed. On July 1 IRB Barcelona opened their doors for ‘Family Day’ and provided a unique opportunity for mothers and fathers, grandmothers and
grandfathers, aunts and uncles to come to the lab to take a look for themselves. After an introduction to today’s biomedical research, expertly delivered by IRB Barcelona Director Joan J Guinovart, sci-entist volunteers led guests on an adventure through some of the activities currently going on at the Institute. This time, instead of just explaining those Western Blots, our researchers actually got to demonstrate them. Here’s what some of our guests had to say:
VIEWPOINT Family Day at IRB Barcelona
“I was amazed by the passion
of the scientists we met. They
explained the difficult work
they do with such wonderful
enthusiasm. Who ever knew
that a tiny fruit fly could be so
important for human health?
I’ll never look at a fly the same
way again!”
Rosa Montsant Age 60
“I have visited my son Marc be-
fore, so I already knew a bit about
his work. I think it’s very impor-
tant for us to have the oppor-
tunity to see how our sons and
daughters spend their days. Sci-
ence requires a lot of dedication
and sacrifice, and activities like
this help us to understand this.”
Joan GuiuAge 66
“In my family we’ve had the mis-
fortune of seeing the devastating
effects of cancer from very close.
My sister died from uterine can-
cer metastasis a few years ago. I
wanted to get a first-hand view
of the research efforts directed to
find new strategies to fight this
terrible disease.”
Enriqueta PallarèsAge 71
“We went on the tour about the
structure of proteins and were
surprised about the scale of the
things researchers study. We could
never have imagined that so much
information could be packed into
such a small thing. It was fascinat-
ing to see the technologies scien-
tists use to see the unseeable.”
Vicenta Bertrán, Francesc BernadóAges 72 and 74
A winning dove
A zebra dove, photographed by surprise in Hawaii by IRB Barcelona postdoc-
toral fellow Amelie Stein, made it to the 2010 EMBO Journal cover in April. The photo-graph, which captures in astonishing detail the blue skin around the bird’s eyes, was se-lected by the jury as one of the best submis-sions in the non-scientific section of the 2010 Cover Contest. Bioinformaticist Stein has been an amateur photographer since 2007.
Stockpiling awards
Four IRB Barcelona scientists
were recently on a winning
streak and saw their research work ac-
knowledged by several prize-award-
ing institutions.
IRB Barcelona Oncology Pro-
gramme coordinator and group leader
Eduard Batlle was awarded in June
the ‘Banc de Sabadell’ Prize for
Biomedical Research for his break-
through studies on the onset of colon
cancer and its progression from initial
stages to the formation of aggressive
tumors (read story on page 2).
The Spanish Biophysics Society
(SBE) also gave its two annual prizes to
two IRB Barcelona researchers in July:
Group leader and computational biol-
ogy expert Modesto Orozco received
the Bruker Prize for his exceptional
contributions to the study of nucleic
acid structures and the dy-
namic properties of macro-
molecules and their interac-
tions. Pau Bernadó, research
associate at the Biomolecu-
lar NMR Group, was also
awarded the SBE Biophysics
Prize for Young Investiga-
tors for his pioneering work
on complex macromolecular
interactions.
Chemists and molecu-
lar pharmacologists at the
Institute also had a winner
in May. Programme coor-
dinator and group leader Ernest Giralt trav-
eled to Greece to receive the 2nd Dimitrios
Theodoropoulos Memorial Lecture Award,
a prize given by the European Peptide So-
ciety, for his crucial contributions to peptide
chemistry.
Photo: A
. Stein
in vivoJuly 2010 | Issue 11
06
FACES TO NAMES
Angel R Nebreda. Group Leader, IRB Barcelona Signalling and Cell Cycle Laboratory
“The main problem with cancer is that it goes unnoticed
and when it’s detected it’s often too late”
Biochemist and new IRB Barcelona group leader Angel R Nebreda (Spain, 1961)
has lived most of his research life as an expa-triate, spending many years at the National Institutes of Health (US), the Cancer Re-search UK and the European Molecular Bi-ology Laboratory (Germany). Tired of living abroad, he moved back to Spain in 2004 to lead a group on cancer research at the Span-ish National Cancer Center. Nebreda joined IRB Barcelona in July to run the Signalling and Cell Cycle Laboratory. His research will mainly focus on unraveling the role of the protein kinase p38 MAPK in lung, colon and breast cancer, exploring the rewiring of tumor cells, and finding the connections be-tween inflammation and tumors.
- What’s the link between cancer and in-flammation?
“Inflammation in the organism is a necessary and natural response to help the body over-come external attacks. Even in the early stag-es of cancer, inflammatory cells help to fight tumors. The problem is when inflammation becomes recurrent and leads to chronic dis-eases such as colitis or hepatitis, where an excessive inflammation can facilitate the path for cancer cells to proliferate quicker and de-velop a tumor.”
- Can a healthy body have cancer cells?
“It’s likely that any person over the age of forty has a number of cancer cells in the body, but our immune system knows how to fight and destroy them.”
- Is cancer a silent killer?
“Our organism has a great capacity to keep
ANNA ALSINA
Photo: S. A
rmengou
“Smoking is clearly a direct cause of lung can-cer, but there are other factors that can lead to it such as exposure to carcinogens in the air, or inherited genetic mutations. A person with a genetic predisposition has a high risk of devel-oping lung cancer before turning sixty five.”
- A group of scientists in the United States recently warned against fraudulent treat-ments using stem cells. What’s your advice?
“It’s a fact that there are centers offering stem cell treatments that have no clear ben-efit. There are also many experimental thera-pies though that are not strictly a fraud but that have not been proven to be completely safe or that have very low probabilities of success. If a person is dying and there’s no turning back, it’s a survival instinct to want to try something even if the probability for it to work is only 1%. The latest advances in research have brought about unthinkable therapies and treatments. It’s not that com-mon yet, but in the US there are companies that are already freezing people when they die hoping that maybe in fifty or a hundred years they will be resuscitated. There are many things being done today that thirty years ago would have been considered sci-ence fiction.”
- What’s your opinion on the Spanish gov-ernment’s plans to reduce research funding?
“Funding cuts on research are always nega-tive, especially in a country like Spain where the public budget for science is lower than in many other countries such as the US, Japan, Germany or England. Science in Spain has seen a great improvement in the past years. The consequences can be really bad. It would be a shame to take a step backwards.”
African clawed frogs follow Nebreda wherever he goes. His new research group will be using this aquatic species with short claws to unravel the myster-ies of the cell cycle and its connections to cancer. “Xenopus laevis is one of the best systems available for biochemical studies because it has up to 20,000 oo-cytes and their maturation period is ex-traordinarily quick,” he says. Nebreda started to use this species in cancer re-search with Nobel Laureate Tim Hunt in the nineties.
working even when things go wrong inter-nally. When we were doing experiments to track down cancer cells in the lung we were surprised to see that mice had a completely normal behavior and showed no symptoms of disease. When we performed an autopsy we realized that their lungs were totally riddled with tumors. The main problem with cancer is that it goes unnoticed and when it’s detected it’s often too late. That’s why prevention and early detection are crucial.”
- There have been a lot of preventive efforts against smoking but there are people who die of lung cancer that have never smoked.
A focus on African frogs
in vivoJuly 2010 | Issue 11
07
Moving under one roof
The IRB Bar-celona English Editing Service launched a new initiative for the
research community in June. Tanya Yates now offers regular walk-in ses-sions where researchers can bring their scientific papers, theses or re-search proposals and discuss good editing practices. For more informa-tion, email Tanya at [email protected].
A new editing initiative
IRB Barcelona scientist Lluís Ribas de Pou-plana translat-
ed his benchwork into plain language to give a ‘microconference’ for all au-diences at the 4th edition of ‘Festa de la Ciència’. Held on June 12-13 at the Ciutadella Park, the event was orga-nized by the Institute for Culture of Barcelona and included more than 60 outreach activities.
Simplifying science
The Barcelona Science Park (PCB) has a new face in management. Maria Terrades was
appointed new PCB managing director in May. Besides her duties at the Park, Terrades will also be serving IRB Barcelona through her role as a member of the Board of Trustees, the governing body of the Institute.
Holder of a degree in Economics and Busi-ness Sciences from the University of Barcelona and a PDD from IESE Business School, Terrades started out in Price Waterhouse and three years later moved on to Sarriopapel & Celulosa. Over more than 17 years, she has held several positions
A new managing director
of responsibility in AGBAR (a company with a turnover of 3,000 million euros and 14,000 employees), during the most recent period undertaking management duties for Treasury and Finances. Terrades has taught the subject of Budgeting and Budgetary Control on the masters course in Corporate Finance and Ac-counting Management organized by IDEC at the Pompeu Fabra University, and has partici-pated as a speaker in several meetings held by the Institute for International Research (IIR).
Researchers at IRB Barcelona won’t need to get out of the
building and cross the street any-more for internal collaborations. The research groups led by Lluís Ribas de Pouplana and Ramon Eritja moved their labs from the Helix to the Clus-ter building this summer, where all the other IRB Barcelona laboratories and core facilities are located. The Administration offices also expanded this summer to include the first floor, where the ITS department and new meeting rooms are now located.
IN BRIEF Mission: discover your workplace
Why do we use flies in the labs? What does
Impact Factor mean? What are the Core
Facilites for? How is cancer metastasis studied?
How do drugs work in a cell and how are they
designed? For scientists, the answers to these
questions are clear but they may not be that
simple for administrative staff.
The mission that the IRB Barcelona Direc-
torate has entrusted us with is to provide non-
scientific personnel the opportunity to discover
the beauty of biomedical science and to make
them aware of their contribution to the success
of the research carried out at IRB Barcelona.
Under the slogan ‘Mission: discover your
workplace’, we have already organized two ses-
sions, each of which was attended by more than
forty people. The first session took place on
April 27. As it was the initial talk, we presented
the Institute, the scientific programmes, and the
different types of labs and their composition.
We also outlined the research cycle – starting
from basic questions and moving on to the new
treatments that reach patients - as well as the
impact of the science performed at IRB Barce-
lona on our society. The second session, fo-
cused specifically on science, was devoted to
the cell, a common theme that runs through
each and every lab. It was organized with the
invaluable help of researchers Ernest Giralt,
Oscar Martorell, Maria Tarragona and Delia
Zafra.
The attendees were very enthusiastic and
participative, asking many questions and cre-
ating a dynamic atmosphere. The thematic
sessions will continue in the autumn with
new exciting topics. If you wish to join us,
contact [email protected].
NEWS FROM THE PARK
(From left to right) Clara Caminal, Cristina Horcajada and Sònia Armengou during the first session of ‘Mission: Discover your Workplace’.
PCB
S. Armengou/ C. Caminal/ C. Horcajada
in vivoJuly 2010 | Issue 11
NEW AT IRB BARCELONASPOTLIGHT
Published by the Institute for Research in Biomedicine. Office of Communications & External Relations. Barcelona Science Park. Baldiri Reixac, 10. 08028 Barcelona, Spain. www.irbbarcelona.org. Editor: Anna Alsina. Associate Editor: Sarah Sherwood. Contributors: Sònia Armengou, Nahia Barbería, Clara Caminal, Jorge Domínguez, Cristina Horcajada, Tanya Yates. Design: Aymerich Comunicació. Printing: Puresa. Graphic Production: La Trama. Legal deposit: B-1730-2010. This document has been printed on recycled paper. To subscribe or unsubscribe from in vivo email [email protected] © IRB Barcelona
Camille Stephan-Otto (Mexico, 1978) has been work-ing with formulas and statistical parameters for a few weeks. She recently moved from the Memorial Sloan Kettering Can-cer Center in New York to IRB Barcelona to work as a senior research officer at the Biostatisticts/Bioinformatics Unit. Her
mission will be to help IRB Barcelona researchers to come up with new hypoth-eses by performing genetic regulation and next generation sequencing analyses. A biomathematician by training, Camille started out doing her doctoral work on the origin of life and evolution. She decided to enter the field of biomedicine because she was looking for more tangible results. “One of the advantages of mathematics in daily life is that they help you order your thoughts and see the logical side of things more clearly. Using math in a creative way in biology is the real challenge,” she says.
A cross-Atlantic connection
IRB Barcelona has made a training connec-tion across the Atlantic this summer. Biolo-
gy student Stephanie Lin is one of two students to come from the Massachusetts Institute of Technology (MIT). She will spend three months working in the Gene Translation Laboratory as part of the MISTI program, an MIT internship initiative to work abroad during the summer.
- Why did you choose Spain?
“The programme also offers internships in Bra-zil, China, France, Germany, India, Israel, Italy, Japan and Mexico but I chose Spain because I had never been to Europe before and I was really impressed by the biomedical research at IRB Barcelona. It’s really blooming.”
- What is your mission at IRB Barcelona this summer?
“I’m working with PhD student Tanit Guitart to develop a model for mitochondrial diseases. I’ve never worked with fruit flies before and re-ally enjoy exploring these tiny insects under the microscope.”
- What was your reaction when you found out about your internship acceptance?
“I was a bit nervous but really excited about the idea because I had been looking for this intern-ship opportunity for over a year.”
- What’s your career dream?
“I want to combine research and medical prac-tice to treat infectious diseases such as malaria, toxoplasma and viruses. I really love the idea of working closely with patients, and hope to be-come an infectious diseases specialist.”
Biotechnologist Carlos Bertoncini (Argentina, 1977) recently left the University of Cambridge and joined Xavier Salvatella’s lab as a postdoctoral fellow to work on a very ambitious project: discovering how protein aggregates lead to neuronal death in diseases such as Parkinson’s and Al-zheimer’s. Holder of a Marie Curie Grant, he says that his decision to come to the Institute was influenced by the fact that “this is one of the few places in Europe that has all the techniques and facilities I need under one roof.” He’s settling nicely into the city and does not plan yet to return to Argentina, at least for a while.
Observing science from backstage at the Cell Division Laboratory as a lab manager has inspired Nuria López (Spain, 1981) to pursue a scientific career. A technical en-gineer in chemistry by training, she has recently left IRB Barcelona to take up a position as a PhD student at the In-stitute for Bioengineering of Catalonia. Nuria will be working for the first time on the virulence factors of Pseudomonas aeruginosa, a pathogen that can cause fatal infections in cystic fibrosis patients.
ON THE MOVE
Photo: N
. Barbería
Chemical physicist Federica Battistini (Italy, 1982) has recently joined Modesto Orozco’s group as a postdoctoral researcher. Several years ago she moved from her hometown of Milan to Sheffield to pursue her doctoral studies and now with her PhD under her belt, she has decided to come to
work at IRB Barcelona. Federica’s task will be to refine a model that predicts where and why nucleosomes, the structures that organize and package DNA within the cell, are formed with the goal of gaining a better understanding of how the genome is organized. Although Federica will be working mainly at the computer, she will also need to maintain close collaborations with laboratories to test the predictions obtained from her model.